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and metaanalysis of randomized trials
Gabriele Saccone, MD; Anju Suhag, MD; Vincenzo Berghella, MDWe sought to evaluate the efficacy of maintenance tocolysis with 17-alpha-hydrox-
yprogesterone caproate (17P) compared to control (either placebo or no treatment) in
singleton gestations with arrested preterm labor (PTL), in a metaanalysis of randomized
trials. Electronic databases (MEDLINE, OVID, Scopus, ClinicalTrials.gov, and the
Cochrane Central Register of Controlled Trials) were searched from 1966 through July
2014. Key words included “progesterone,” “tocolysis,” “preterm labor,” and “17-alpha-
hydroxyprogesterone caproate.” We performed a metaanalysis of randomized trials of
singleton gestations with arrested PTL and treated with maintenance tocolysis with either
17P or control. Primary outcome was preterm birth (PTB)<37 weeks. This metaanalysis
was performed following the Preferred Reporting Items for Systematic Reviews and
Metaanalyses (PRISMA) statement. The protocol was registered with PROSPERO
(registration no: CRD42014013473). Five randomized trials met inclusion criteria,
including 426 women. Women with a singleton gestation who received 17P maintenance
tocolysis for arrested PTL had a similar rate of PTB<37 weeks (42% vs 51%; relative risk
[RR], 0.78; 95% confidence intervals [CI], 0.50e1.22) and PTB <34 weeks (25% vs
34%; RR, 0.60; 95% CI, 0.28e1.12) compared to controls. Women who received 17P
had significantly later gestational age at delivery (mean difference, 2.28 weeks; 95% CI,
1.46e13.51), longer latency (mean difference, 8.36 days; 95% CI, 3.20e13.51), and
higher birthweight (mean difference, 224.30 g; 95% CI, 70.81e377.74) as compared to
controls. Other secondary outcomes including incidences of recurrent PTL, neonatal
death, admission to neonatal intensive care unit, neonatal respiratory distress syndrome,
bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis, and
neonatal sepsis were similar in both groups. Maintenance tocolysis with 17P after
arrested PTL is not associated with prevention of PTB compared to placebo or no
treatment in a metaanalysis of the available randomized trials. As 17P for maintenance
tocolysis is associated with a significant prolongation of pregnancy, and significantly
higher birthweight, further research is suggested.
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health care spending on infants.4 Glob-
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JULY 2015delaying births caused by PTL. Primary
tocolysis is tocolysis given on initial
presentation ofwomenwith PTL. Inmost
of these women, PTL stops. Their risk of
PTB remains high and so some have
advocated use of maintenance tocolysis,
ie, tocolysis after arrested PTL. So far, no
maintenance tocolytic agent has been
shown to be beneﬁcial in preventing
PTB. Recently, progesterone has been
used successfully for prevention of PTB,
in particular in asymptomatic women
with either short cervical length6,7 or
prior spontaneous PTB.8 The efﬁcacy of
progesterone in preventing PTB in
symptomatic womenwith arrested PTL is
not clear.
The objective of this metaanalysis
was to evaluate the efﬁcacy of mainte-
nance tocolysis with 17-alpha-hydrox-
yprogesterone caproate (17P) compared
to placebo or no treatment in singleton
gestations with arrested PTL in a meta-
analysis of randomized trials.
Materials and methods
Searches were performed in MEDLINE,
OVID, Scopus, ClinicalTrials.gov, and
the Cochrane Central Register of
Controlled Trials with the use of a com-
bination of key words and text words
related to “progesterone,” “tocolysis,”
“preterm labor,” and “17-alpha-hydrox-
yprogesterone caproate” from 1966
through July 2014. To locate additional
publications, we reviewed proceedings of
international society meetings on PTB
and tocolysis and bibliographies of iden-
tiﬁed studies and reviews articles. No
restrictions for language or geographic
location were applied.
We included randomized trials of
singleton gestations that had arrested
PTL and then were randomized to
maintenance tocolysis treatment with
either 17P or control (either placebo or
no treatment). All published randomized
FIGURE 1
Flow of information through different phases of review
RCT, randomized controlled trial.
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ajog.org Systematic Reviewsstudies on progesterone tocolysis were
carefully reviewed. Exclusion criteria
included quasirandomized trials, main-
tenance tocolysis in womenwith preterm
premature rupture of membrane
(PPROM) and maintenance tocolysis
with vaginal progesterone.
Data abstraction was completed by 3
independent investigators (G.S., A.S.,
V.B.). Each investigator independently
abstracted data from each study and
analyzed data separately. Differences were
reviewed, and further resolved by com-
mon review of the entire data set. Data
abstracted included number of study pa-
tients, number of patients in intervention
and control groups, dosage of 17P, route
and frequency of administration of 17P,
gestational age at randomization, gesta-
tional age at delivery, interval from
randomization to delivery (ie, latency),
PTB <37 weeks, PTB <34 weeks, spon-
taneous PTB <37 weeks, spontaneous
PTB <34 weeks, birthweight, neonatal
death, admission to neonatal intensive
care unit (NICU), neonatal respiratory
distress syndrome (RDS), broncho-
pulmonary dysplasia (BPD), intraven-
tricular hemorrhage (IVH), necrotizing
enterocolitis (NEC), and neonatal sepsis.
For studies that did not stratify data,
composite data were extracted. When
possible, authors of included trials were
contacted for missing data.
The risk of bias in each included study
was assessed by using the criteria outlined
in the Cochrane Handbook for System-
atic Reviews of Interventions.9 Seven
domains related to risk of bias were
assessed in each included trial since there
is evidence that these issues are associated
with biased estimates of treatment effect:
(1) random sequence generation; (2)
allocation concealment; (3) blinding of
participants and personnel; (4) blinding
of outcome assessment; (5) incomplete
outcome data; (6) selective reporting; and
(7) other bias. Review authors’ judg-
ments were categorized as low, high, or
unclear risk of bias.9
The primary outcome included PTB
<37 weeks. Secondary outcomes
included PTB <34 weeks, gestational of
delivery, latency, spontaneous PTB <37
weeks, spontaneous PTB <34 weeks,
birthweight, neonatal death, NICU,RDS, BPD, IVH, NEC, and neonatal
sepsis.
The data analysis was completed
independently by authors (G.S., A.S.,
V.B.) using Review Manager 5.3 (The
Nordic Cochrane Centre, Cochrane
Collaboration, Copenhagen, Denmark).
The completed analyses were then
compared, and any difference was re-
solved with review of the entire data set
and independent analysis. Statistical het-
erogeneity between studies was assessed
using the Cochrane Q statistic and Hig-
gins I2 statistics. In case of statistical sig-
niﬁcant heterogeneity (P value of the
Cochrane Q statistic < .1) the random
effects model of DerSimonian and Laird
was used to obtain the pooled relative
risk (RR) estimate, otherwise a ﬁxedJULY 2015 Aeffect models was planned. The summary
measures were reported as RR, with 95%
conﬁdence interval (CI). P value less than
.05was considered statistically signiﬁcant.
Before data extraction, the protocol
was registered with PROSPERO (regis-
tration number: CRD42014013473).10
The metaanalysis was performed
following the Preferred Reporting Items
for Systematic Reviews andMetaanalyses
(PRISMA) statement.11
This study had no funding source.
Results
Twenty-one trials on progesterone as
tocolytic were identiﬁed.8,12-31 Eleven
randomized trials evaluating the effect
of progesterone in maintenance thera-
py during PTL were identiﬁed.21-31 Fivemerican Journal of Obstetrics& Gynecology 17
TABLE 1
Descriptive data for each trial
Variable
Facchinetti
et al,28 2007
Rozenberg
et al,29 2012
Regmi
et al,30 2012
Lotfalizadeh
et al,27 2013
Briery
et al,31 2014 Total
Study location Italy France Nepal Iran United States e
No. of patients,
n (intervention vs
control)
60 (30 vs 30) 188 (94 vs 94) 60 (29 vs 31) 73 (37 vs 36) 45 (22 vs 23) 426 (212
vs 214)
Dose, mg 341 500 250 250 250 e
Frequency of
17P treatment
Twice weekly Twice weekly Weekly Weekly Weekly e
Control No treatment No treatment No treatment No treatment Placebo e
Primary
tocolytic
agent
Atosiban Nifedipine,
nicardipine, or
salbutamol
Nifedipine Magnesium
sulfate or
nifedipine
Magnesium
sulfate, calcium
channel
blockers, or
antiprostaglandin
drugs
e
Range GA at
randomization,
wk
From 25þ0
to 33þ6
From 24þ0
to 31þ6
From 28þ0
to 34þ6
From 26þ0
to 36þ0
From 20þ0
to 30þ6
e
Mean GA at
randomization,
wk
30 vs 30 28 vs 28a 33 vs 33 34 vs 33 29 vs 27 Mean
difference
0.50 wk
(95% CI,
0.24e1.25)a
Study primary
outcomes
CL shortening at
discharge,
and at day 7 and
21 of discharge
Latency period Latency
period
and rate of
recurrent
PTL within
48 h
Rate of
recurrent
PTL
Preterm
delivery
<37 wk
e
Data are presented as 17P vs placebo.
CI, confidence interval; CL, cervical length; GA, gestational age; PTL, preterm labor; 17P, 17-alpha-hydroxyprogesterone caproate.
a GA at randomization of Rozenberg et al29 in 2012 was not included in analysis because SD was not reported.
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Systematic Reviews ajog.orgwere excluded because vaginal proges-
terone was evaluated21,23-26; 1 was
excluded because women with preterm
rupture of the membranes were evalu-
ated.22 Five trials that met inclusion
criteria for this metaanalysis were
analyzed.27-31 No similar systematic re-
view was found. Figure 1 shows the ﬂow
diagram of information through the
different phases of the review.
Descriptive data for each trial are
presented in Table 1. A total of 426
singleton gestations with arrested PTL
were included. Most studies used 17P
250 mg intramuscularly weekly. Four of
5 used no treatment as control.31
The quality of randomized controlled
trials included in our metaanalysis was18 American Journal of Obstetrics& Gynecologyassessed by the Cochrane Collaboration’s
tool9 (Figure 2). All studies had low risk
of bias in incomplete outcome data and
selective reporting. One study was dou-
ble blind.31 Figure 3 shows funnel plot
for assessing publication bias for PTB
<37 weeks; the symmetric plot sug-
gested no publication bias (Figure 3).
Three studies deﬁned PTL as the
presence of at least 6 contractions in 30
minutes accompany to cervical
changes28,30,31; one deﬁned it as the
presence of at least 4 contractions per
minute, accompanied by 2-cm dilata-
tion;27 the other one deﬁned it as painful
uterine contractions at least 2 per 10
minutes accompanied by cervical length
<25 mm.29 Regarding the tocolyticJULY 2015regimens that were used for patients in
the included studies, 1 study used mag-
nesium sulfate or nifedipine27; 1 used
magnesium sulfate, calcium channel
blockers, or antiprostaglandin drugs31; 1
used atosiban28; whereas the other 2
used nifedipine or other calcium channel
blockers29,30 (Table 1).
Of the 426 singleton gestations
included in the 5 trials,27-31 212 (49.8%)
were randomized to 17P, while 214
(50.2%) to control. Women with a
singleton gestation who received 17P
maintenance tocolysis for arrested
PTL had a similar rate of PTB <37
weeks (42% vs 51%; RR, 0.78; 95% CI,
0.50e1.22) (Table 2 and Figure 4) and
PTB <34 weeks (25% vs 34%; RR, 0.60;
FIGURE 2
Assessment of risk of bias
A, Summary of risk of bias for each trial: low (þ), high (e), or unclear (?).9 B, Each risk of bias item presented as percentages across all included studies.
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Funnel plot for assessing publication bias
RR, relative risk.
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ajog.org Systematic Reviews95% CI, 0.28e1.12) compared to con-
trols. Women who received 17P had
signiﬁcantly later gestational age at de-
livery (mean difference, 2.28 weeks;
95% CI, 1.46e3.10), longer latency
(mean difference, 8.36 days; 95% CI
3.20e13.51), and higher birthweight
(mean difference, 224.30 g; 95% CI,
70.87e377.74) as compared to control
group. Other secondary outcomes
including incidences of recurrent PTL,
neonatal death, NICU, RDS, BPD, IVH,
NEC, and sepsis were similar in both
groups (Table 2). Data about sponta-
neous PTB <37 weeks and spontaneous
PTB <34 weeks were not available.
Comment
This metaanalysis of pooled data of 5
randomized controlled trials evaluating
17P treatment for maintenance tocolysis
after arrested PTL shows that mainte-
nance tocolysis with 17P is not associ-
ated with prevention of PTB compared
to controls (placebo or no treatment).
Latency from randomization to deliveryJULY 2015 American Journal of Obstetrics& Gynecology 19
TABLE 2
Primary and secondary outcomes
Variable
Facchinetti
et al,28 2007
Rozenberg
et al,29 2012
Regmi
et al,30 2012
Lotfalizadeh
et al,27 2013
Briery
et al,31 2014 Total RR (95% CI)
No. of patients 60 (30 vs 30) 188 (94 vs 94) 60 (29 vs 31) 73 (37 vs 36) 45 (22 vs 23) 426 (212 vs 214) e
PTB <37 wk 5/30 vs 17/30 37/94 vs 36/94 N/A N/A 19/22 vs 22/33 61/146 (42%) vs 75/147 (51%) 0.78 (0.50e1.22)
PTB <34 wk N/A 15/94 vs 19/94 N/A N/A 14/22 vs 21/23 29/116 (25%) vs 40/117 (34%) 0.60 (0.28e1.12)
Recurrent PTL N/A N/A 11/29 vs 20/31 N/A N/A 11/29 (38%) vs 20/31 (65%) 0.59 (0.34e1.00)
Mean GA delivery, wk N/A 38 vs 38a 37 vs 34 N/A 32 vs 30 e Mean difference
2.28 wk (95% CI, 1.46e3.10)a,b
Mean latency, d N/A 61 vs 63a 25 vs 16 N/A 23 vs 16 e Mean difference 8.36 d
(95% CI, 3.20e13.51)a,b
Mean birthweight, g 3103 vs 2809 2930 vs 2850a 2903 vs 2781 N/A 1693 vs 1536 e Mean difference 224.30 g
(70.87e377.74)a,b
Neonatal death N/A 0/94 vs 0/94 N/A N/A 0/22 vs 3/23 0/116 (0%) vs 3/117 (3%) 0.15 (0.01e2.73)
Admission in NICU N/A 24/94 vs 16/94 3/29 vs 2/31 8/37 vs 14/36 N/A 35/160 (22%) vs 32/161 (20%) 1.09 (0.71e1.66)
RDS N/A 14/94 vs 12/94 3/29 vs 2/31 N/A 7/22 vs 10/23 24/145 (16%) vs 24/148 (16%) 1.02 (0.62e1.69)
BPD N/A 2/94 vs 1/94 N/A N/A N/A 2/94 (2%) vs 1/94 (1%) 2.02 (0.18e22.68)
IVH N/A N/A N/A N/A 0/22 vs 6/23 0/22 (0%) vs 6/23 (26%) 0.08 (0.11e1.35)
NEC N/A 1/94 vs 1/94 N/A N/A 0/22 vs 3/23 1/116 (1%) vs 4/117 (3%) 0.34 (0.05e2.13)
Sepsis N/A N/A 2/29 vs 2/31 N/A 1/22 vs 7/23 3/51 (6%) vs 9/54 (17%) 0.35 (0.10e1.25)
Data are presented as number 17-alpha-hydroxyprogesterone caproate vs number placebo.
BPD, bronchopulmonary dysplasia; CI, confidence interval; GA, gestational age; IVH, intraventricular hemorrhage; N/A, not available; NEC, necrotizing enterocolitis; NICU, neonatal intensive care unit; PTB, preterm birth; PTL, preterm labor; RDS, respiratory distress
syndrome; RR, relative risk.
a GA at delivery, latency, and birthweight of Rozenberg et al29 in 2012 were not included in analysis because SD was not reported; b Statistically significant.
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FIGURE 4
Forest plot analysis of PTB at <37 weeks of gestation for singletons with prior PTB28,29,31
CI, confidence interval; M-H, Mantel-Haenszel; PTB, preterm birth.
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the 17P group compared to controls.
Women who received 17P were ran-
domized about half a week later
regarding gestational age, and delivered
about 2 weeks later compared to con-
trols. Regarding neonatal outcomes,
women who received 17P had babies
with a signiﬁcantly higher birthweight as
compared to the control group, while
other neonatal outcomes were similar.
PTL commonly precedes PTB. Toco-
lytics are often used for short-term
prolongation of the pregnancy, to allow
the obstetricians to administer antenatal
corticosteroids for fetal maturation,
and magnesium sulfate for neuro-
protection, as well as the transport of
patients to tertiary care centers with
level III NICUs.32 After successful pri-
mary tocolysis for steroid beneﬁt,
maintenance tocolysis does not seems
to prevent PTB and improve neonatal
outcomes.32 Compared to placebo,
maintenance tocolysis with oral beta-
mimetics,33 terbutaline pump,34 calcium
channel blockers,35-37 cyclooxygenase-2
inhibitors,38-40 magnesium sulfate,41 or
oxytocin receptor antagonist42 (atosi-
ban) have not been associated with pre-
vention of PTB. Maintenance tocolysis
with progesterone has been studied in
randomized trials, but so far guidelines
have not commented on its use,32 and
this intervention is not routinely dis-
cussed or used in clinical practice.
Only 1 other metaanalysis evaluated
use of progesterone for treatment of
PTL.43 The Cochrane Review on pro-
gestational agents for treating threatenedor established PTL included a subgroup
analysis of progesterone formaintenance
tocolysis in women with both arrested
PTL and PPROM together.43 Moreover,
their analysis combined 3 formulation of
progesterone (17P, natural or vaginal
progesterone, and oral progesterone)
together and did not include all available
randomized controlled trials. Including
PTL and PPROM together, as well as
different formulations of progesterone,
makes clinical use of these data limited.
One of the strengths of our study is
inclusion of only randomized trials on
17P maintenance tocolysis in women
with arrested PTL. Included trials clearly
deﬁned PTL as preterm contractions
with cervical change. The pooled data
represent a relatively large group of pa-
tients treated with 17P maintenance
tocolysis, compared mostly to no treat-
ment, or placebo. Most studies had low
risk of bias by Cochrane Collaboration’s
tool.9 All trials assessed the incidence of
PTB, and the majority assessed some
neonatal outcomes. Another strength of
our study is that it is the only reported
metaanalysis of 17P for maintenance
tocolysis in women with arrested PTL.
Limitations of our study are those
inherent to any other metaanalysis.
The risk for PTB might have been
different in the trials. For example, most
trials (except 128) did not report if study
subjects had prior PTB or had other risk
factors for PTB. The primary tocolysis
regimen was different in the included
trials. The dosage and frequency of
administration of 17P was somewhat
different in various trials. Only 1 of the 5JULY 2015 Atrials included the sample size calcula-
tion; however the authors were unable to
complete full enrollment of the study
subjects due to relocation of one of the
study authors.31 Other limitations of our
metaanalysis are that only 1 trial of 5 had
as primary outcome PTB <37 weeks,31
and the limited information about
neonatal outcome. Furthermore, only 3
trials had data on the primary outcome
variable of PTB <37 weeks and these 3
trials all utilized a different concentra-
tion and dosing interval for 17P. The
heterogeneity between trials was high for
PTB <37 weeks. Lastly, the sample sizes
in the various subgroups are not of suf-
ﬁcient size to rule out a type II error for
the outcome variables measured.
In this metaanalysis of the pertinent
randomized trials, maintenance tocolysis
with 17P after arrested PTL was not
associated with prevention of PTB, but
there was a signiﬁcant 8 days’ prolonga-
tion of pregnancy, and signiﬁcantly higher
birthweight. Given that there was also no
beneﬁt in other neonatal outcomes, 17P
maintenance tocolysis cannotbe currently
recommended for clinical use, but further
research is necessary. We observed that
with anaof 0.05and80%power, a sample
size of 480 patients in each group is
required to detect a reduction in PTB<37
weeks from 51% to 42%. -
REFERENCES
1. American College of Obstetricians and Gy-
necologists Committee on Practice Bulletins-
Obstetrics. Management of preterm labor.
ACOG Practice bulletin no. 43. Int J Gynaecol
Obstet 2003;82:127-35.merican Journal of Obstetrics& Gynecology 21
Systematic Reviews ajog.org2. Martin JA, Hamilton BE, Sutton PD, et al.
Births: ﬁnal data for 2005. Natl Vital Stat Rep
2007;56:1-103.
3. McCormick MC. The contribution of low birth
weight to infant mortality and childhood
morbidity. N Engl J Med 1985;312:82-90.
4. Lewit EM, Baker LS, Corman H, Shiono PH.
The direct cost of low birth weight. Future Child
1995;5:32-6.
5. Lawn JE, Cousens S, Zupan J; for the
Neonatal Survival Steering Team. Four million
neonatal deaths: When? Where? Why? Lancet
2005;365:891-900.
6. Fonseca EB, Celik E, Parra M, Singh M,
Nicolaides KH. Progesterone and the risk of
preterm birth among women with a short cervix.
N Engl J Med 2007;357:462-9.
7. Hassan SS, Romero R, Vidyadhari D, et al.
Vaginal progesterone reduces the rate of pre-
term birth in women with a sonographic short
cervix: a multicenter, randomized, double-blind,
placebo-controlled trial. Ultrasound Obstet
Gynecol 2011;38:18-31.
8. Meis PJ, Klebanoff M, Thom E, et al. Pre-
vention of recurrent preterm delivery by 17
alpha-hydroxyprogesterone caproate. N Engl J
Med 2003;348:2379-85.
9. Higgins JPT, AltmanDG,Sterne JAC.Chapter
8: Assessing risk of bias in included studies. In:
Higgins JPT, Green S, eds. Cochrane hand-
book for systematic reviews of interventions,
version 5.1.0 (update March 2011). The
Cochrane Collaboration, 2011. Available at:
www.cochrane-handbook.org. Accessed Aug.
10, 2014.
10. PROSPERO: International prospective
register of systematic reviews, 2014:
CRD42014013473. Available at: www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID¼CR
D42014013473. Accessed Aug. 10, 2014.
11. Moher D, Liberati A, Tetzlaff J, Altman DG.
Preferred reporting items for systematic reviews
and meta-analyses: the PRISMA statement.
J Clin Epidemiol 2009;62:1006-12.
12. da Fonseca EB, Bittar RE, Carvalho MH,
Zugaib M. Prophylactic administration of pro-
gesterone by vaginal suppository to reduce the
incidence of spontaneous preterm birth in
women at increased risk: a randomized
placebo-controlled double-blind study. Am J
Obstet Gynecol 2003;188:419-24.
13. Majihi P, Bagga R, Kalra J, Sharma M.
Intravaginal use of natural micronized proges-
terone to prevent pre-term birth: a randomized
trial in India. J Obstet Gynaecol 2009;29:493-8.
14. Norman JE, Mackenzie F, Owen P, et al.
Progesterone for the prevention of preterm birth
in twin pregnancy (STOPPIT): a randomized,
double-blind, placebo-controlled study and
meta-analysis. Lancet 2009;373:2034-40.
15. Lim AC, Schuit E, Papatsonis D, et al. Effect
of 17-alpha hydroxyprogesterone caproate on
cervical length in twin pregnancies. Ultrasound
Obstet Gynecol 2012;40:426-30.22 American Journal of Obstetrics& Gynecology16. Tan PC, King AS, Vallikkannu N, Omar SZ.
Single dose 17 alpha hydroxyprogesterone
caproate in preterm labor: a randomized trial.
Arch Gynecol Obstet 2012;285:585-90.
17. Grobman WA, Thom EA, Spong CY, et al.
17 Alpha hydroxyprogesterone caproate to
prevent prematurity in nulliparas with cervical
length less than 30 mm. Am J Obstet Gynecol
2012;207:390.
18. Senat MV, Porcher R, Winer N, et al. Pre-
vention of preterm delivery by 17 alpha hydrox-
yprogesterone caproate in asymptomatic twin
pregnancies with a short cervix: a randomized
controlled trial. Am J Obstet Gynecol 2013;208:
194.
19. Aﬂatoonian A, Amouzegar H. Dehghani
Firouzabadi R. Efﬁcacy of 17alpha-hydrox-
yprogesterone on decreasing preterm labor in
ART pregnancies: a randomized clinical trial. Iran
J Reprod Med 2013;11:785-90.
20. Briery CM, Veillon EW, Klauser CK, et al.
Progesterone does not prevent preterm births in
women with twins. South Med J 2009;102:
900-4.
21. ChoudharyM, Suneja A, Vaid NB, Guleria K,
Faridi MM. Maintenance tocolysis with oral
micronized progesterone for prevention of pre-
term birth after arrested preterm labor. Int J
Gynaecol Obstet 2014;126:60-3.
22. Coombs CA, Garite TJ, Maurel K, et al. 17-
hydroxyprogesterone caproate to prolong preg-
nancy after preterm rupture of the membranes:
early termination of a double-blind, randomized
clinical trial. BMC Res Notes 2011;29:568.
23. Borna S, Sahabi N. Progesterone for main-
tenance tocolytic therapy after threatened pre-
term labor: a randomized controlled trial. Aust N
Z J Obstet Gynaecol 2008;48:58-63.
24. Sharami SH, Zahiri Z, Shakiba M, Milani F.
Maintenance therapy by vaginal progesterone
after threatened idiopathic preterm labor: a
randomized placebo-controlled double blind
trial. Int J Fertil Steril 2010;4:45-50.
25. Arikan I, Barut A, HarmaM, Harma IM. Effect
of progesterone as a tocolytic and in mainte-
nance therapy during preterm labor. Gynecol
Obstet Invest 2011;72:269-73.
26. Areia A, Fonseca E, Moura P. Progesterone
use after successful treatment of threatened
pre-term delivery. J Obstet Gynaecol 2013;33:
678-81.
27. Lotfalizadeh M, Ghomian N, Reyhani A. The
effects of progesterone therapy on the gestation
length and reduction of neonatal complications
in patients who had received tocolytic therapy
for acute phase of preterm labor. Iran Red
Crescent Med J 2013;15:e7947.
28. Facchinetti F, Paganelli S, Comitini G,
Dante G, Volpe A. Cervical length changes
during preterm cervical ripening: effects of 17-
hydroxyprogesterone caproate. Am J Obstet
Gynecol 2007;196:453.e1-4.
29. Rozenberg P, Chauveaud A, Deruelle P,
et al. Prevention of preterm delivery afterJULY 2015successful tocolysis in preterm labor by 17
alpha-hydroxyprogesterone caproate: a ran-
domized controlled trial. Am J Obstet Gynecol
2012;206:206.e1-9.
30. Regmi MC, Rijal P, Agrawal A, Uprety D.
Progesterone for prevention of recurrent pre-
term labor after arrested preterm laborea ran-
domized controlled trial. Gynecol Obstet
2012;2:125.
31. Briery CM, Klauser CK, Martin RW,
Magann EF, Chauhan SP, Morrison JC. The use
of 17-hydroxy progesterone in women with
arrested preterm labor: a randomized clinical trial.
J Matern Fetal Neonatal Med 2014;27:1892-6.
32. American College of Obstetricians and Gy-
necologists Committee on Practice Bulletins-
Obstetrics. Management of preterm labor.
ACOGPractice bulletin no. 127. Obstet Gynecol
2012;119:1308-17.
33. Dodd JM, Crowther CA, DareMR, et al. Oral
betamimetics for maintenance therapy after
threatened preterm labor. Cochrane Database
Syst Rev 2006;25:CD003927.
34. Nanda K, Cook LA, Gallo MF, et al. Terbu-
taline pump maintenance therapy after threat-
ened preterm labor for preventing preterm birth.
Cochrane Database Syst Rev 2002;4:
CD003933.
35. Carr DB, Clark AL, Kernek K, et al. Mainte-
nance oral nifedipine for preterm labor: a ran-
domized clinical trial. Am J Obstet Gynecol
1999;181:822-7.
36. Lyell DJ, Pullen KM, Mannan J, et al. Main-
tenance nifedipine tocolysis compared with
placeboea randomized controlled trial. Obstet
Gynecol 2008;112:1221-6.
37. Sayin NC, Varol FG, Balkanli-Kaplan P, et al.
Oral nifedipine maintenance therapy after acute
intravenous tocolysis in preterm labor. J Perinat
Med 2004;32:220-4.
38. Carlan SJ, O’Brien WF, Jones MH, et al.
Outpatient oral sulindac to prevent recurrence of
preterm labor. Obstet Gynecol 1995;85:769-74.
39. Humprey RG, Bartﬁeld MC, Carlan SJ, et al.
Sulindac to prevent recurrent preterm labor: a
randomized controlled trial. Obstet Gynecol
2001;98:555-62.
40. Bivins HA, Newman RB, Fyfe DA, et al.
Randomized trial of oral indomethacin and ter-
butaline for the long-term suppression of pre-
term labor. Am J Obstet Gynecol 1993;169:
1065-70.
41. Han S, Crowther CA, Moore V. Magnesium
maintenance therapy for preventing preterm
birth after threatened preterm labor. Cochrane
Database Syst Rev 2010;7:CD000940.
42. Valenzuela GJ, Sanchez-Ramos L,
Romero R, et al. Maintenance treatment of pre-
term labor with the oxytocin antagonist atosiban.
Am J Obstet Gynecol 2000;182:1184-90.
43. Su LL, SamuelM, Chong YS. Progestational
agents for treating threatened or established
preterm labor. Cochrane Database Syst Rev
2014;1:CD006700.
